Active, not recruitingNCT05382156

Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome

Studying OBSOLETE: Cushing syndrome

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: RECORDATI GROUP
Principal Investigator: Mario Maldonado, MD
Recordati AG - Head of Clinical Development
Intervention: Osilodrostat(drug)
Enrollment: 206 enrolled
Eligibility: 18 years · All sexes
Timeline: 2022 – 2027

Study locations (30)

Barrow Neurological Institute, Phoenix, Arizona, United States
Emory University School, Atlanta, Georgia, United States
Northwestern University, Chicago, Illinois, United States
Indiana University Schl-med, Indianapolis, Indiana, United States
St Elizabeth Physicians, Covington, Kentucky, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
University of Michigan, Ann Arbor, Michigan, United States
Mayo Clinic - Rochester, Rochester, Minnesota, United States
Washington University School of Medicine, St Louis, Missouri, United States
NYU Grossman School of Medicine, New York, New York, United States
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York, New York, United States
Endocrinology Research Associates, Inc., Columbus, Ohio, United States
Oregon Health And Science University, Portland, Oregon, United States
University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States
Froedtert Hospital, Milwaukee, Wisconsin, United States
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05382156 on ClinicalTrials.gov

Other trials for OBSOLETE: Cushing syndrome

Additional recruiting or active studies for the same condition.

See all trials for OBSOLETE: Cushing syndrome →

← Back to all trials